<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">89801</article-id><article-id pub-id-type="doi">10.7554/eLife.89801</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-321445"><name><surname>Du</surname><given-names>Zhanwei</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2020-767X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-113485"><name><surname>Wang</surname><given-names>Lin</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5371-2138</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-322907"><name><surname>Bai</surname><given-names>Yuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-322908"><name><surname>Liu</surname><given-names>Yunhu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-322909"><name><surname>Lau</surname><given-names>Eric HY</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-322910"><name><surname>Galvani</surname><given-names>Alison P</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273068"><name><surname>Krug</surname><given-names>Robert M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3754-5034</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-36262"><name><surname>Cowling</surname><given-names>Benjamin John</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6297-7154</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-94158"><name><surname>Meyers</surname><given-names>Lauren A</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Li Ka Shing Faculty of Medicine</institution>, <institution>University of Hong Kong</institution>, <addr-line><named-content content-type="city">Hong Kong</named-content></addr-line>, <country>Hong Kong</country></aff><aff id="aff2"><institution content-type="dept">Department of Genetics</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Center for Infectious Disease Modeling and Analysis</institution>, <institution>Yale University</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Molecular Biosciences</institution>, <institution>The University of Texas at Austin</institution>, <addr-line><named-content content-type="city">Austin</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Li Ka Shing Faculty of Medicine</institution>, <institution>University of Hong Kong</institution>, <addr-line><named-content content-type="city">Hong Kong</named-content></addr-line>, <country>China</country></aff><aff id="aff6"><institution content-type="dept">Department of Integrative Biology</institution>, <institution>The University of Texas at Austin</institution>, <addr-line><named-content content-type="city">Austin</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-128727"><name><surname>McCaw</surname><given-names>James M</given-names></name><role>Reviewing editor</role><aff><institution>University of Melbourne</institution>, <country>Australia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>bcowling@hku.hk</email> (BC);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>laurenmeyers@austin.utexas.edu</email> (LM);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>04</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e89801</elocation-id><history><date date-type="received"><day>31</day><month>05</month><year>2023</year></date><date date-type="accepted"><day>03</day><month>04</month><year>2024</year></date></history><permissions><copyright-statement>Â© 2024, Du et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Du et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-89801-v1.pdf"/><abstract><p>Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics to electronic health records data from 208 hospitalized patients in Hong Kong, we estimate that Paxlovid can inhibit over 90% of viral replication. However, its effectiveness critically depends on the timing of treatment. If treatment is initiated three days after symptoms first appear, we estimate a 17% chance of a post-treatment viral rebound and a 12% (95% CI: 0%-16%) reduction in overall infectiousness for non-rebound cases. Earlier treatment significantly elevates the risk of rebound without further reducing infectiousness, whereas starting beyond five days reduces its efficacy in curbing peak viral shedding. Among the 104 patients who received Paxlovid, 62% began treatment within an optimal three-to-five-day day window after symptoms appeared. Our findings indicate that broader global access to Paxlovid, coupled with appropriately timed treatment, can mitigate the severity and transmission of SARS-Cov-2.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003452</institution-id><institution>Innovation and Technology Commission</institution></institution-wrap></funding-source><award-id>AIR@InnoHK</award-id><principal-award-recipient><name><surname>Du</surname><given-names>Zhanwei</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005847</institution-id><institution>Health and Medical Research Fund</institution></institution-wrap></funding-source><award-id>07210147</award-id><principal-award-recipient><name><surname>Du</surname><given-names>Zhanwei</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82304204</award-id><principal-award-recipient><name><surname>Bai</surname><given-names>Yuan</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI151176</award-id><principal-award-recipient><name><surname>Meyers</surname><given-names>Lauren A</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000030</institution-id><institution>Centers for Disease Control and Prevention</institution></institution-wrap></funding-source><award-id>U01IP001136</award-id><principal-award-recipient><name><surname>Meyers</surname><given-names>Lauren A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Benjamin John Cowling, reports honoraria from AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer,Sanofi Pasteur, and Roche. The authors report no other potential conflicts of interest.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Individual patient-informed consent was not required in this study using anonymized data.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data used in this study can be accessed through Github: https://github.com/ZhanweiDU/PaxHK/.</p></sec><supplementary-material><ext-link xlink:href="elife-89801-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>